Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein
Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio
Source: finanznachrichten.de
